StoxSun Pharmaceutical Industries vs Zydus Lifesciences: share price & financials comparison
NSE: SUNPHARMA vs ZYDUSLIFE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sun Pharmaceutical Industries vs Zydus Lifesciences at a glance
Sun Pharmaceutical Industries (SUNPHARMA) has a market capitalisation of ₹4,51,068 Cr, against ₹1,18,752 Cr for Zydus Lifesciences (ZYDUSLIFE). Over the past year Zydus Lifesciences has returned +22.5%, compared with +11.2% for Sun Pharmaceutical Industries. On valuation, Zydus Lifesciences trades at a lower P/E of 28.4 versus 41.1. Zydus Lifesciences earns a higher return on equity (15.0% vs 12.3%). Sun Pharmaceutical Industries comes out ahead on size, profitability and financial health. Zydus Lifesciences comes out ahead on valuation, growth, momentum and technicals. Across the scored metrics below, Sun Pharmaceutical Industries leads on 5 and Zydus Lifesciences on 13. On StoxGud's 10-point checklist, Sun Pharmaceutical Industries scores 8/10 and Zydus Lifesciences scores 10/10.
| Metric | Sun Pharmaceutical Industries | Zydus Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹4,51,068 Cr | ₹1,18,752 Cr |
| Revenue (latest FY) | ₹58,462 Cr | ₹27,148 Cr |
| Net profit (latest FY) | ₹11,479 Cr | ₹5,040 Cr |
| Valuation | ||
| P/E | 41.1 | 28.4 |
| P/B | 5.05 | 4.27 |
| Dividend yield | 0.87% | 0.93% |
| Profitability | ||
| Return on equity | 12.3% | 15.0% |
| Net profit margin | 17.8% | 13.8% |
| Operating margin | 29.3% | 27.0% |
| Growth | ||
| Revenue growth (YoY) | +11.9% | +29.2% |
| Net profit growth (YoY) | -36.2% | -26.5% |
| Revenue CAGR (multi-year) | +11.8% | +12.4% |
| Financial health | ||
| Debt to equity | 0.03 | 0.48 |
| Momentum | ||
| 1-month return | +6.2% | +5.1% |
| 1-year return | +11.2% | +22.5% |
| 3-year CAGR | +16.9% | +24.2% |
| 5-year CAGR | +18.3% | +19.3% |
| 10-year CAGR | +10.7% | +12.8% |
| Distance from 52W high | -6.1% | -4.5% |
| Technicals | ||
| RSI (14) | 81 | 63 |
| Price vs 200-day avg | +3.6% | +13.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sun Pharmaceutical Industries | Zydus Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 8/10 | 10/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sun Pharmaceutical Industries or Zydus Lifesciences?
Sun Pharmaceutical Industries has a market cap of ₹4,51,068 Cr and Zydus Lifesciences has a market cap of ₹1,18,752 Cr as of 13 Nov 2026.
Which has a lower P/E, Sun Pharmaceutical Industries or Zydus Lifesciences?
Zydus Lifesciences has the lower P/E: Sun Pharmaceutical Industries trades at 41.1 and Zydus Lifesciences at 28.4.
Which gave better returns in the last year, Sun Pharmaceutical Industries or Zydus Lifesciences?
Zydus Lifesciences did better: Sun Pharmaceutical Industries returned +11.2% and Zydus Lifesciences returned +22.5% over one year.
What is the difference between Sun Pharmaceutical Industries and Zydus Lifesciences?
Both are NSE-listed companies in Healthcare. Sun Pharmaceutical Industries is about 3.8 times the size of Zydus Lifesciences by market cap. In the latest financial year Sun Pharmaceutical Industries reported revenue of ₹58,462 Cr and Zydus Lifesciences ₹27,148 Cr. Operating margin is 29.3% for Sun Pharmaceutical Industries and 27.0% for Zydus Lifesciences. Debt to equity is 0.03 for Sun Pharmaceutical Industries and 0.48 for Zydus Lifesciences.
Which is better, Sun Pharmaceutical Industries or Zydus Lifesciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sun Pharmaceutical Industries leads on 5 and Zydus Lifesciences on 13. Sun Pharmaceutical Industries is ahead on size, profitability and financial health. Zydus Lifesciences is ahead on valuation, growth, momentum and technicals. On StoxGud's rules-based checklist Sun Pharmaceutical Industries scores 8/10 and Zydus Lifesciences scores 10/10. This is information, not advice: consult a SEBI-registered adviser before investing.